Skip to main content
Top
Published in: Arthritis Research & Therapy 5/2013

Open Access 01-10-2013 | Research article

Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis

Authors: Jaya Prakash Chalise, Sudeep Chenna Narendra, Bhesh Raj Paudyal, Mattias Magnusson

Published in: Arthritis Research & Therapy | Issue 5/2013

Login to get access

Abstract

Introduction

Interferon alpha (IFN-α) has a complex role in autoimmunity, in that it may both enhance and prevent inflammation. We have previously shown that the presence of IFN-α at sensitization protects against subsequent antigen-triggered arthritis. To understand this tolerogenic mechanism, we performed a descriptive, hypothesis-generating study of cellular and humoral responses associated with IFN-α-mediated protection against arthritis.

Methods

Arthritis was evaluated at day 28 in mice given a subcutaneous injection of methylated bovine serum albumin (mBSA), together with Freund adjuvant and 0 to 5,000 U IFN-α at days 1 and 7, followed by intraarticular injection of mBSA alone at day 21. The effect of IFN-α on mBSA-specific IgG1, IgG2a, IgG2b, IgA, and IgE was evaluated by enzyme-linked immunosorbent assay (ELISA). Cytokines in circulation and in ex vivo cultures on mBSA restimulation was evaluated with ELISA and Luminex, and the identity of cytokine-producing cells by fluorescence-activated cell sorting (FACS) analysis.

Results

Administration of IFN-α protected mice from arthritis in a dose-dependent manner but had no effect on antigen-specific antibody levels. However, IFN-α did inhibit the initial increase of IL-6, IL-10, IL-12, and TNF, and the recall response induced by intraarticular mBSA challenge of IL-1β, IL-10, IL-12, TNF, IFN-γ, and IL-17 in serum. IFN-α decreased both macrophage and CD4+ T cell-derived IFN-γ production, whereas IL-17 was decreased only in CD4+ T cells. Ex vivo, in mBSA-restimulated spleen and lymph node cell cultures, the inhibitory effect of in vivo administration of IFN-α on proinflammatory cytokine production was clearly apparent, but had a time limit. An earlier macrophage-derived, and stronger activation of the antiinflammatory cytokine transforming growth factor beta (TGF-β) was observed in IFN-α-treated animals, combined with an increase in CD4+ T cells producing TGF-β when arthritis was triggered by mBSA (day 21). Presence of IFN-α at immunizations also prevented the reduction in TGF-β production, which was induced by the intraarticular mBSA injection triggering arthritis in control animals.

Conclusions

Administration of IFN-α has a profound effect on the cellular response to mBSA plus adjuvant, but does not affect antigen-specific Ig production. By including IFN-α at immunizations, spleen and lymph node cells inhibit their repertoire of antigen-induced proinflammatory cytokines while enhancing antiinflammatory TGF-β production, first in macrophages, and later also in CD4+ T cells. On intraarticular antigen challenge, this antiinflammatory state is reenforced, manifested as inhibition of proinflammatory recall responses and preservation of TGF-β levels. This may explain why IFN-α protects against antigen-induced arthritis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006, 25: 383-392. 10.1016/j.immuni.2006.08.010.CrossRefPubMed Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006, 25: 383-392. 10.1016/j.immuni.2006.08.010.CrossRefPubMed
2.
go back to reference Stubgen JP: Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 2009, 212: 132-141. 10.1016/j.jneuroim.2009.04.015.CrossRefPubMed Stubgen JP: Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 2009, 212: 132-141. 10.1016/j.jneuroim.2009.04.015.CrossRefPubMed
3.
go back to reference Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E: Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005, 115: 1100-PubMedCentral Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E: Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest. 2005, 115: 1100-PubMedCentral
4.
go back to reference Magnusson M, Zare F, Tarkowski A: Requirement of type I interferon signaling for arthritis triggered by double-stranded RNA. Arthritis Rheum. 2006, 54: 148-157. 10.1002/art.21517.CrossRefPubMed Magnusson M, Zare F, Tarkowski A: Requirement of type I interferon signaling for arthritis triggered by double-stranded RNA. Arthritis Rheum. 2006, 54: 148-157. 10.1002/art.21517.CrossRefPubMed
5.
go back to reference Ying F, Chalise JP, Narendra SC, Magnusson M: Type I IFN protects against antigen-induced arthritis. Eur J Immunol. 2011, 41: 1687-1695. 10.1002/eji.201040956.CrossRefPubMed Ying F, Chalise JP, Narendra SC, Magnusson M: Type I IFN protects against antigen-induced arthritis. Eur J Immunol. 2011, 41: 1687-1695. 10.1002/eji.201040956.CrossRefPubMed
6.
go back to reference Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B: Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011, 70: 1905-1913. 10.1136/ard.2010.144485.CrossRefPubMed Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B: Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011, 70: 1905-1913. 10.1136/ard.2010.144485.CrossRefPubMed
7.
go back to reference Oliver BJ, Kohli E, Kasper LH: Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci. 2011, 302: 96-105. 10.1016/j.jns.2010.11.003.CrossRefPubMed Oliver BJ, Kohli E, Kasper LH: Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. J Neurol Sci. 2011, 302: 96-105. 10.1016/j.jns.2010.11.003.CrossRefPubMed
8.
go back to reference Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, Tarkowski A: Arthritogenic properties of double-stranded (viral) RNA. J Immunol. 2004, 172: 5656-5663.CrossRefPubMed Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, Tarkowski A: Arthritogenic properties of double-stranded (viral) RNA. J Immunol. 2004, 172: 5656-5663.CrossRefPubMed
9.
go back to reference Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002, 169: 1459-1466.CrossRefPubMed Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol. 2002, 169: 1459-1466.CrossRefPubMed
10.
go back to reference Yarilina A, DiCarlo E, Ivashkiv LB: Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol. 2007, 178: 2204-2211.CrossRefPubMed Yarilina A, DiCarlo E, Ivashkiv LB: Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J Immunol. 2007, 178: 2204-2211.CrossRefPubMed
11.
go back to reference Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS: Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis. 2009, 68: 257-263. 10.1136/ard.2008.095356.PubMedCentralCrossRefPubMed Corr M, Boyle DL, Ronacher L, Flores N, Firestein GS: Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis. 2009, 68: 257-263. 10.1136/ard.2008.095356.PubMedCentralCrossRefPubMed
12.
go back to reference Ronnblom L, Alm GV, Eloranta ML: The type I interferon system in the development of lupus. Semin Immunol. 2011, 23: 113-121. 10.1016/j.smim.2011.01.009.CrossRefPubMed Ronnblom L, Alm GV, Eloranta ML: The type I interferon system in the development of lupus. Semin Immunol. 2011, 23: 113-121. 10.1016/j.smim.2011.01.009.CrossRefPubMed
13.
go back to reference Mangini AJ, Lafyatis R, Van Seventer JM: Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108: 11-23. 10.1196/annals.1422.002.CrossRefPubMed Mangini AJ, Lafyatis R, Van Seventer JM: Type I interferons inhibition of inflammatory T helper cell responses in systemic lupus erythematosus. Ann N Y Acad Sci. 2007, 1108: 11-23. 10.1196/annals.1422.002.CrossRefPubMed
14.
go back to reference Kalliolias GD, Ivashkiv LB: Overview of the biology of type I interferons. Arthritis Res Ther. 2010, 12 (Suppl 1): S1-10.1186/ar2881. doi:10.1186/ar2881PubMedCentralCrossRefPubMed Kalliolias GD, Ivashkiv LB: Overview of the biology of type I interferons. Arthritis Res Ther. 2010, 12 (Suppl 1): S1-10.1186/ar2881. doi:10.1186/ar2881PubMedCentralCrossRefPubMed
15.
go back to reference Brackertz D, Mitchell GF, Vadas MA, Mackay IR: Studies on antigen-induced arthritis in mice, III. Cell and serum transfer experiments. J Immunol. 1977, 118: 1645-1648.PubMed Brackertz D, Mitchell GF, Vadas MA, Mackay IR: Studies on antigen-induced arthritis in mice, III. Cell and serum transfer experiments. J Immunol. 1977, 118: 1645-1648.PubMed
16.
go back to reference Martin E, Capini C, Duggan E, Lutzky VP, Stumbles P, Pettit AR, O’Sullivan B, Thomas R: Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum. 2007, 56: 2255-2266. 10.1002/art.22655.CrossRefPubMed Martin E, Capini C, Duggan E, Lutzky VP, Stumbles P, Pettit AR, O’Sullivan B, Thomas R: Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum. 2007, 56: 2255-2266. 10.1002/art.22655.CrossRefPubMed
17.
go back to reference Svard A, Kastbom A, Sommarin Y, Skogh T: Salivary IgA antibodies to cyclic citrullinated peptides (CCP) in rheumatoid arthritis. Immunobiology. 2013, 218 (2): 232-237. 10.1016/j.imbio.2012.04.011. doi:10.1016/j.imbio.2012.04.011CrossRefPubMed Svard A, Kastbom A, Sommarin Y, Skogh T: Salivary IgA antibodies to cyclic citrullinated peptides (CCP) in rheumatoid arthritis. Immunobiology. 2013, 218 (2): 232-237. 10.1016/j.imbio.2012.04.011. doi:10.1016/j.imbio.2012.04.011CrossRefPubMed
18.
go back to reference Ekerfelt C, Andersson M, Olausson A, Bergstrom S, Hultman P: Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice. Clin Exp Immunol. 2007, 150: 189-197. 10.1111/j.1365-2249.2007.03474.x.PubMedCentralCrossRefPubMed Ekerfelt C, Andersson M, Olausson A, Bergstrom S, Hultman P: Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice. Clin Exp Immunol. 2007, 150: 189-197. 10.1111/j.1365-2249.2007.03474.x.PubMedCentralCrossRefPubMed
19.
go back to reference Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001, 14: 461-470. 10.1016/S1074-7613(01)00126-1.CrossRefPubMed Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF: Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001, 14: 461-470. 10.1016/S1074-7613(01)00126-1.CrossRefPubMed
20.
go back to reference Thompson JM, Whitmore AC, Staats HF, Johnston R: The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine. 2008, 26: 4998-5003. 10.1016/j.vaccine.2008.07.011.PubMedCentralCrossRefPubMed Thompson JM, Whitmore AC, Staats HF, Johnston R: The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine. 2008, 26: 4998-5003. 10.1016/j.vaccine.2008.07.011.PubMedCentralCrossRefPubMed
21.
go back to reference Gonzalez-Quintela A, Alende MR, Lojo S, Perez LF, Padin E, Tome S, Vidal C: Total serum IgE levels in chronic hepatitis C: influence of interferon alpha therapy. Int Arch Allergy Immunol. 2001, 125: 176-181. 10.1159/000053812.CrossRefPubMed Gonzalez-Quintela A, Alende MR, Lojo S, Perez LF, Padin E, Tome S, Vidal C: Total serum IgE levels in chronic hepatitis C: influence of interferon alpha therapy. Int Arch Allergy Immunol. 2001, 125: 176-181. 10.1159/000053812.CrossRefPubMed
22.
go back to reference Pene J, Rousset F, Brier F, Chretien I, Bonifay JY, Spits H, Yokota T, Arai N, Arai K, Banchereau J: IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natal Acad Sci USA. 1988, 85: 6880-6884. 10.1073/pnas.85.18.6880.CrossRef Pene J, Rousset F, Brier F, Chretien I, Bonifay JY, Spits H, Yokota T, Arai N, Arai K, Banchereau J: IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natal Acad Sci USA. 1988, 85: 6880-6884. 10.1073/pnas.85.18.6880.CrossRef
23.
24.
go back to reference Astray B, Herbert’s E, Moodily KD: A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res. 2011, 31: 927-940. 10.1089/jir.2011.0094.CrossRef Astray B, Herbert’s E, Moodily KD: A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res. 2011, 31: 927-940. 10.1089/jir.2011.0094.CrossRef
25.
go back to reference Take PP, Kaleen JR: Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011, 13: S5- Take PP, Kaleen JR: Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther. 2011, 13: S5-
26.
go back to reference Henning son L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, van de Loo FA, Gjertsson I: Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PloS One. 2012, 7: e49731-10.1371/journal.pone.0049731.CrossRef Henning son L, Eneljung T, Jirholt P, Tengvall S, Lidberg U, van den Berg WB, van de Loo FA, Gjertsson I: Disease-dependent local IL-10 production ameliorates collagen induced arthritis in mice. PloS One. 2012, 7: e49731-10.1371/journal.pone.0049731.CrossRef
27.
go back to reference Jung S, Park YK, Lee H, Shin JH, Lee GR, Park SH: TGF-beta-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses. Exp Mol Med. 2010, 42: 187-194. 10.3858/emm.2010.42.3.019.PubMedCentralCrossRefPubMed Jung S, Park YK, Lee H, Shin JH, Lee GR, Park SH: TGF-beta-treated antigen presenting cells suppress collagen-induced arthritis through the promotion of Th2 responses. Exp Mol Med. 2010, 42: 187-194. 10.3858/emm.2010.42.3.019.PubMedCentralCrossRefPubMed
28.
go back to reference Woods JM, Amin MA, Katschke KJ, Volin MV, Ruth JH, Connors MA, Woodruff DC, Kurata H, Arai KI, Haines GK: Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther. 2002, 13: 381-393. 10.1089/10430340252792512.CrossRefPubMed Woods JM, Amin MA, Katschke KJ, Volin MV, Ruth JH, Connors MA, Woodruff DC, Kurata H, Arai KI, Haines GK: Interleukin-13 gene therapy reduces inflammation, vascularization, and bony destruction in rat adjuvant-induced arthritis. Hum Gene Ther. 2002, 13: 381-393. 10.1089/10430340252792512.CrossRefPubMed
29.
go back to reference van den Berg WB, Joosten LA, van Lent PL: Murine antigen-induced arthritis. Methods Mol Med. 2007, 136: 243-253. 10.1007/978-1-59745-402-5_18.CrossRefPubMed van den Berg WB, Joosten LA, van Lent PL: Murine antigen-induced arthritis. Methods Mol Med. 2007, 136: 243-253. 10.1007/978-1-59745-402-5_18.CrossRefPubMed
30.
go back to reference Perfetto SP, Chattopadhyay PK, Roederer M: Seventeen-colour flow cytometry: unravelling the immune system. Nature Rev Immunol. 2004, 4: 648-655. 10.1038/nri1416.CrossRef Perfetto SP, Chattopadhyay PK, Roederer M: Seventeen-colour flow cytometry: unravelling the immune system. Nature Rev Immunol. 2004, 4: 648-655. 10.1038/nri1416.CrossRef
31.
go back to reference Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G: Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol. 2003, 171: 6466-6477.CrossRefPubMed Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G: Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol. 2003, 171: 6466-6477.CrossRefPubMed
32.
go back to reference Notley CA, Brown MA, Wright GP, Ehrenstein MR: Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol. 2011, 186: 4967-4972. 10.4049/jimmunol.1003021.CrossRefPubMed Notley CA, Brown MA, Wright GP, Ehrenstein MR: Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J Immunol. 2011, 186: 4967-4972. 10.4049/jimmunol.1003021.CrossRefPubMed
33.
go back to reference Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP: Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006, 54: 158-168. 10.1002/art.21537.CrossRefPubMed Wong PK, Quinn JM, Sims NA, van Nieuwenhuijze A, Campbell IK, Wicks IP: Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006, 54: 158-168. 10.1002/art.21537.CrossRefPubMed
34.
go back to reference Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51: v3-v11. 10.1093/rheumatology/kes113.CrossRef Choy E: Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012, 51: v3-v11. 10.1093/rheumatology/kes113.CrossRef
35.
go back to reference de Paus RA, van Wengen A, Schmidt I, Visser M, Verdegaal EM, van Dissel JT, van de Vosse E: Inhibition of the type I immune responses of human monocytes by IFN-alpha and IFN-beta. Cytokine. 2013, 61: 645-655. 10.1016/j.cyto.2012.12.005.CrossRefPubMed de Paus RA, van Wengen A, Schmidt I, Visser M, Verdegaal EM, van Dissel JT, van de Vosse E: Inhibition of the type I immune responses of human monocytes by IFN-alpha and IFN-beta. Cytokine. 2013, 61: 645-655. 10.1016/j.cyto.2012.12.005.CrossRefPubMed
36.
go back to reference Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM: Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood. 2011, 118: 2170-2173. 10.1182/blood-2011-03-340992.CrossRefPubMed Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM: Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood. 2011, 118: 2170-2173. 10.1182/blood-2011-03-340992.CrossRefPubMed
37.
go back to reference Dikopoulos N, Bertoletti A, Kroger A, Hauser H, Schirmbeck R, Reimann J: Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol. 2005, 174: 99-109.CrossRefPubMed Dikopoulos N, Bertoletti A, Kroger A, Hauser H, Schirmbeck R, Reimann J: Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol. 2005, 174: 99-109.CrossRefPubMed
38.
go back to reference Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL: IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009, 183: 2475-2483. 10.4049/jimmunol.0900986.PubMedCentralCrossRefPubMed Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL: IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol. 2009, 183: 2475-2483. 10.4049/jimmunol.0900986.PubMedCentralCrossRefPubMed
39.
go back to reference Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003, 198: 1875-1886. 10.1084/jem.20030152.PubMedCentralCrossRefPubMed Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003, 198: 1875-1886. 10.1084/jem.20030152.PubMedCentralCrossRefPubMed
40.
go back to reference Kimura A, Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010, 40: 1830-1835. 10.1002/eji.201040391.CrossRefPubMed Kimura A, Kishimoto T: IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010, 40: 1830-1835. 10.1002/eji.201040391.CrossRefPubMed
41.
go back to reference Xu L, Wang C, Zhou Y, Ren T, Wen Z: CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol Lett. 2012, 142: 55-63. 10.1016/j.imlet.2011.12.006.CrossRefPubMed Xu L, Wang C, Zhou Y, Ren T, Wen Z: CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol Lett. 2012, 142: 55-63. 10.1016/j.imlet.2011.12.006.CrossRefPubMed
42.
go back to reference Ou-Yang HF, Hu XB, Ti XY, Shi JR, Li SJ, Qi HW, Wu CG: Suppression of allergic airway inflammation in a mouse model by Der p2 recombined BCG. Immunology. 2009, 128: e343-e352. 10.1111/j.1365-2567.2008.02970.x.PubMedCentralCrossRefPubMed Ou-Yang HF, Hu XB, Ti XY, Shi JR, Li SJ, Qi HW, Wu CG: Suppression of allergic airway inflammation in a mouse model by Der p2 recombined BCG. Immunology. 2009, 128: e343-e352. 10.1111/j.1365-2567.2008.02970.x.PubMedCentralCrossRefPubMed
43.
go back to reference Gjertsson I, Laurie KL, Devitt J, Howe SJ, Thrasher AJ, Holmdahl R, Gustafsson K: Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol Ther. 2009, 17: 632-640. 10.1038/mt.2009.299.PubMedCentralCrossRefPubMed Gjertsson I, Laurie KL, Devitt J, Howe SJ, Thrasher AJ, Holmdahl R, Gustafsson K: Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis. Mol Ther. 2009, 17: 632-640. 10.1038/mt.2009.299.PubMedCentralCrossRefPubMed
44.
go back to reference Santos LM, Al-Sabbagh A, Londono A, Weiner HL: Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer’s patches of SJL mice. Cell Immunol. 1994, 157: 439-447. 10.1006/cimm.1994.1240.CrossRefPubMed Santos LM, Al-Sabbagh A, Londono A, Weiner HL: Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer’s patches of SJL mice. Cell Immunol. 1994, 157: 439-447. 10.1006/cimm.1994.1240.CrossRefPubMed
45.
go back to reference Jittimanee J, Sermswan RW, Kaewraemruaen C, Barta JR, Macinnes JI, Maleewong W, Wongratanacheewin S: Protective immunization of hamsters against Opisthorchis viverrini infection is associated with the reduction of TGF-beta expression. Acta Tropica. 2012, 122: 189-195. 10.1016/j.actatropica.2012.01.010.CrossRefPubMed Jittimanee J, Sermswan RW, Kaewraemruaen C, Barta JR, Macinnes JI, Maleewong W, Wongratanacheewin S: Protective immunization of hamsters against Opisthorchis viverrini infection is associated with the reduction of TGF-beta expression. Acta Tropica. 2012, 122: 189-195. 10.1016/j.actatropica.2012.01.010.CrossRefPubMed
46.
go back to reference Kochetkova I, Thornburg T, Callis G, Pascual DW: Segregated regulatory CD39+CD4+ T cell function: TGF-beta-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol. 2011, 187: 4654-4666. 10.4049/jimmunol.1100530.PubMedCentralCrossRefPubMed Kochetkova I, Thornburg T, Callis G, Pascual DW: Segregated regulatory CD39+CD4+ T cell function: TGF-beta-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis. J Immunol. 2011, 187: 4654-4666. 10.4049/jimmunol.1100530.PubMedCentralCrossRefPubMed
Metadata
Title
Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis
Authors
Jaya Prakash Chalise
Sudeep Chenna Narendra
Bhesh Raj Paudyal
Mattias Magnusson
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2013
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4326

Other articles of this Issue 5/2013

Arthritis Research & Therapy 5/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.